One Way To Get Ahead: Biogen To Test Spinraza Given After Novartis’s Zolgensma

 
• By Mandy Jackson

Biogen said some spinal muscular atrophy patients are currently being treated with Spinraza after receiving the Novartis gene therapy – its main competitor – so it will start a study of the risk/benefit in 2021.

paper plane on white background, Business competition concept.
Treating SMA patients post Zolgensma could give Spinraza sales a boost • Source: Shutterstock

More from Clinical Trials

More from R&D